Syros Pharmaceuticals

Syros Pharmaceuticals (NASDAQ: SYRS) is a therapeutics company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. Syros’ initial focus is in cancer, but the company platform will also be applicable to other therapeutic areas. In 2015, Syros raised a $50M IPO and began trading on the NASDAQ under the ticker symbol “SYRS.”


Company Profile

Syros Pharmaceuticals Logo

Flagship Partners:

  • Doug Cole, Managing Partner
  • Noubar Afeyan, Founder & CEO